SCHEMBL7918358

SCHEMBL7918358

O=C(O)c1ccc2cccc(-c3cc(Cl)ccc3Cl)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.46
PLA2G2D Q9UNK4 1/20 0.46
TSHR P16473 2/20 0.45
ALDH1A1 P00352 1/20 0.44
TP53 P04637 1/20 0.44
TTR P02766 3/20 0.43
SRD5A2 P31213 3/20 0.43
SRD5A1 P18405 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.42
PTPN1 P18031 1/20 0.42
CNR2 P34972 1/20 0.42
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
GAA P10253 1/20 0.41
RAB9A P51151 1/20 0.41
MCL1 Q07820 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
SERPINE1 P05121 1/20 0.41
MAPK1 P28482 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16502529 0.89 SRD5A2 (0.51) TRPV1PLA2G2DTTRSRD5A2SRD5A1
SCHEMBL7919880 0.87 PLA2G2D (0.48) TRPV1PLA2G2DTSHRTTRSRD5A2
SCHEMBL16502458 0.87 PLA2G2D (0.49) TRPV1PLA2G2DTSHRTTRPTPN1
SCHEMBL7918688 0.86 PLA2G2D (0.47) TRPV1PLA2G2DTSHRALDH1A1TTR
SCHEMBL16502676 0.86 SRD5A2 (0.47) TRPV1PLA2G2DTSHRTTRSRD5A2
SCHEMBL7908929 0.84 PLAU (0.48) ALDH1A1TP53KDM4ENPC1RAB9A
SCHEMBL16502526 0.83 GRM2 (0.47) TRPV1PLA2G2DTTRSRD5A2SRD5A1
SCHEMBL16502525 0.83 GRM2 (0.46) TRPV1PLA2G2DALDH1A1TTRSRD5A2
SCHEMBL7918853 0.82 PLA2G2D (0.48) TRPV1PLA2G2DTSHRTTRMRGPRX4
SCHEMBL16502567 0.82 CDH1 (0.49) TRPV1PLA2G2DTSHRSRD5A2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES ASTELLAS PHARMA INC. (JP) 2011-12-15 US disclosed
WO-2010090304-A1 ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306621-A1 ACYLGUANIDINE DERIVATIVES HTR5A, HTR2A, HTR1A TRPV1 899/4885PLA2G2D 841/4885TSHR 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.